about
Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvementsRationale and efficacy of interleukin-1 targeting in Erdheim-Chester diseaseInfluence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium.Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease.Central nervous system involvement in Wegener granulomatosis.Measure of function in rheumatoid arthritis: individualised or classical scales?Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome?Ophthalmologic manifestations of systemic necrotizing vasculitides at diagnosis: a retrospective study of 1286 patients and review of the literature.Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis.Impact of systemic sclerosis on occupational and professional activity with attention to patients with digital ulcers.Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: a retrospective multicenter study.Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome.Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue.Control treatments in biologics trials of rheumatoid arthritis were often not deemed acceptable in the context of care.Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes.The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.Severe deafness associated with Crohn's disease and spondylarthropathy: successful treatment with anti-TNF.Cervical syphilitic spondylodiscitis associated with neurosyphilis.Upregulation of membrane-bound CD40L on CD4+ T cells in women with primary Sjögren's syndrome.2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts.IgG4-related disease associated with renal microaneurysms and polycythaemia.Orbital Myositis and Primary Sjögren Syndrome.Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group databaseEuropean League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: A Complete Picture of Primary Sjögren's Syndrome PatientsScleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controlsIndividualising the Western Ontario and McMaster Universities osteoarthritis index (WOMAC) function subscale: incorporating patient priorities for improvement to measure functional impairment in hip or knee osteoarthritisPattern of demyelination occurring during anti-TNF-α therapy: a French national surveyProgressive osseous heteroplasia: a rare case of late onsetHigh frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients[Periostitis in systemic necrotizing vasculitides: Study of the 4 cases identified among the 1762 patients of the FVSG database and review of the literature]Remittent non-destructive polysynovitis in P-ANCA-positive vasculitis patients with anti-CCP antibodiesReply: To PMID 25779552Epidemiology of primary Sjögren's syndrome in a French multiracial/multiethnic areaSmall fiber neuropathy in Sjögren syndrome: Comparison with other small fiber neuropathiesReplyReply
P50
Q26800693-F55E12C5-A916-4ADB-9EF2-B976D38B16BDQ28291022-660D33A7-E1A6-4CCB-9FF9-5DCBAE38B5ACQ31145428-6F0EFB3D-6EB3-4437-9D97-E7591447E770Q33431030-3EBBA104-698C-4408-BDA6-2EB6E896F213Q33993983-E412CEF1-6384-4E3A-A2B0-901222CD58A5Q34057574-30FBE9A5-E1EB-420E-AF2C-7034C6014DF6Q34663199-0A9312CE-60D0-4072-B0E1-9FF18F1EED23Q35774612-445EBF59-8968-417C-A53C-C7EC0749DB80Q36183852-01A4166B-60BE-4441-A75D-D53BF7697B88Q38070037-8D3095DD-C4CB-4A3C-982A-D9B09D609C5EQ39806562-9D3EB8A8-E358-48F3-9A19-62DA839FBA54Q39949561-F5B50248-6844-4B59-AF4C-A794B8E92BE1Q40143427-CEF18577-0E43-4D65-A5CB-CA1E9CB64A72Q41097622-DDF50715-FFDC-400C-A8C2-F4E71DF6F108Q45235101-29694368-5E76-49F2-A720-174B1A0CE549Q47971791-6BBC5E7F-C613-4CE6-816A-8ADEB12306E7Q48565256-22778CE4-4FFC-43D1-B9D2-A285B8575491Q48654744-9545762C-193E-4FDF-AA5B-6E1AC8E29D66Q50357954-B2E6C5AB-CE73-4C20-924A-CCCF34A9B648Q50433767-1BDA0B88-E6BC-4A85-AA03-65E9983EC662Q51194148-36189A21-834C-4B7D-8B4F-6B7C53028B51Q51358713-7B252F7F-7F57-448B-82BB-A4120979140AQ52990288-29D5F458-27A5-4097-B935-34A774127F52Q53398435-F7E04EA9-AF14-4EBF-8E8A-34A9A2C023BAQ54546316-A98A4A0F-9F17-4E70-9ABD-922EF221F966Q56978051-2D435CBE-9DFE-4853-BAD8-5A1FE21A9EA1Q57612823-D3B6B742-79FC-4EEC-A2CD-71A3FE9A724EQ57612906-8693EAEE-FCD3-4F36-AF5F-2B6D1461F492Q57779885-421D05D3-8AFC-42D4-A8D6-50C030E1FECAQ59399819-31D690AB-3B62-490D-B819-3B84ED0A415CQ79534733-01648950-4EF2-46B4-B1C3-FD39671332D3Q82635832-9567F794-DC4D-4336-BA3A-08354F1F308FQ83371514-EE2EE8AE-7C16-4802-A168-0CEF5AF543BCQ84254937-9ABA8C54-17B1-4AB4-928D-44988B286A17Q86022109-EFEBF0F5-5593-46A7-8A17-050B0816518BQ87319423-6F1D0E96-A873-44F6-A599-D23305BCB26BQ89506247-AF992850-6023-44F3-A255-A815380323CCQ95493382-BF7BF950-E886-45A8-A41A-AA955EA7EE3EQ95534365-19C2BF45-5079-40B0-AE83-51A8DA2657A7
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Raphaele Seror
@ast
Raphaele Seror
@en
Raphaele Seror
@es
Raphaele Seror
@nl
Raphaele Seror
@sl
type
label
Raphaele Seror
@ast
Raphaele Seror
@en
Raphaele Seror
@es
Raphaele Seror
@nl
Raphaele Seror
@sl
prefLabel
Raphaele Seror
@ast
Raphaele Seror
@en
Raphaele Seror
@es
Raphaele Seror
@nl
Raphaele Seror
@sl
P106
P31
P496
0000-0002-5523-1856